The Nuclear Receptor Nur77 Could Improve The Lipid Accumulation In Non-Alcoholic Fatty Liver Disease(NAFLD)in Cooperation With SREBP-1c

Nonalcoholic fatty liver is a chronic disease that has plagued our country and the world’s population.The incidence rate is about 20%,which means there is one non-alcoholic fatty liver carrier every five Chinese people.Even though in FDA recommended "non-alcoholic fatty liver disease diagnosis and treatment guidelines",there is no clear and effective prevention and treatment of non-alcoholic fatty liver drugs.Therefore,it is imminent to clarify the regulatory mechanism of lipid metabolism in liver cells to screen drugs that can improve lipid accumulation.In this study,80 cases were analyzed to try to find the protein that regulates the key transcription factor SREBP-lc in lipid metabolism.We used tissue immunization to detect Nur77 expression in the patient’s liver puncture sample.The results showed that the expression of SREBP-lc was significantly up regulated with the increase of Nur77 expression.Subsequently,we established a model of non-alcoholic fatty liver cells in vitro and in vivo in mice and found that Nur77 was able to respond quickly to lipid changes in the environment within one hour and that the high expression of Nur77 was The degree of improvement in lipid accumulation in the liver.Specifically,we found that Nur77 can bind to the SREBP promoter region to inhibit its mRNA transcription,thereby inhibiting its downstream target gene expression,inhibiting lipid synthesis to improve lipid accumulation.This topic provides a potential target for the prevention of non-alcoholic fatty liver drugs.